- Home
- GERN vs SIBN Comparison
GERN vs SIBN Comparison
Compare GERN & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- SIBN
- Stock Information
- Founded
- GERN 1990
- SIBN 2008
- Country
- GERN United States
- SIBN United States
- Employees
- GERN N/A
- SIBN N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- SIBN Medical/Dental Instruments
- Sector
- GERN Health Care
- SIBN Health Care
- Exchange
- GERN Nasdaq
- SIBN Nasdaq
- Market Cap
- GERN 853.5M
- SIBN 805.4M
- IPO Year
- GERN 1996
- SIBN 2018
- Fundamental
- Price
- GERN $1.51
- SIBN $16.39
- Analyst Decision
- GERN Buy
- SIBN Strong Buy
- Analyst Count
- GERN 7
- SIBN 5
- Target Price
- GERN $4.17
- SIBN $24.40
- AVG Volume (30 Days)
- GERN 10.9M
- SIBN 451.8K
- Earning Date
- GERN 08-07-2025
- SIBN 08-04-2025
- Dividend Yield
- GERN N/A
- SIBN N/A
- EPS Growth
- GERN N/A
- SIBN N/A
- EPS
- GERN N/A
- SIBN N/A
- Revenue
- GERN $116,293,000.00
- SIBN $176,601,000.00
- Revenue This Year
- GERN $160.12
- SIBN $19.48
- Revenue Next Year
- GERN $55.01
- SIBN $16.86
- P/E Ratio
- GERN N/A
- SIBN N/A
- Revenue Growth
- GERN 22264.04
- SIBN 22.60
- 52 Week Low
- GERN $1.17
- SIBN $11.70
- 52 Week High
- GERN $5.06
- SIBN $20.05
- Technical
- Relative Strength Index (RSI)
- GERN 51.36
- SIBN 36.27
- Support Level
- GERN $1.42
- SIBN $17.35
- Resistance Level
- GERN $1.58
- SIBN $19.24
- Average True Range (ATR)
- GERN 0.10
- SIBN 0.61
- MACD
- GERN -0.01
- SIBN -0.40
- Stochastic Oscillator
- GERN 40.00
- SIBN 2.00
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.